Wilson's Disease Trends

• According to DelveInsight's analysis, the Wilson's disease diagnosed prevalent population across the 7MM is expected to grow during the forecast period, driven primarily by improved diagnosis through expanded genetic testing, greater disease awareness, earlier detection, and reduced underdiagnosis, leading to a larger treatable patient pool. 
• Wilson's disease is primarily diagnosed between 5 and 35 years of age, with the highest prevalence in individuals <40 years, according to the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Improved genetic testing and earlier diagnosis are increasing the identified patient population, supporting market expansion. 
• In Japan, approximately 50% diagnosed Wilson's disease cases present with hepatic manifestations, while neurological involvement accounts for ~18%, combined neuro-hepatic disease for ~14%, and other manifestations for ~19%.
• In the UK, there were approximately 580 symptomatic and 90 asymptomatic cases of Wilson’s disease in 2024.
• The absence of routine screening programs and inconsistent access to genetic testing hinder timely identification of Wilson’s disease.

Wilson's Disease Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Wilson's Disease: ~ USD XX million
• Wilson's Disease Growth Rate (2026–2036): ~XX % CAGR

DelveInsight's ‘Wilson's Disease Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Wilson's Disease, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Wilson's Disease Understanding and Diagnostic Algorithm

Wilson's Disease Overview and Diagnosis

Wilson’s Disease is a rare, autosomal recessive genetic disorder caused by mutations in the ATP7B gene, resulting in impaired copper transport and the progressive accumulation of copper in various organs, particularly the liver, brain, and eyes. The disease manifests with a broad spectrum of hepatic, neurological, and psychiatric symptoms, including liver dysfunction, tremors, movement disorders, behavioral changes, and the characteristic Kayser–Fleischer rings. 

Diagnosis

Diagnosis is based on a combination of clinical assessment, serum ceruloplasmin levels, 24-hour urinary copper excretion, ophthalmologic examination, liver biopsy, and genetic testing. Early recognition is critical, as untreated disease can lead to severe organ damage, liver failure, and significant neurological impairment. 

Further details are provided in the report....

Wilson's Disease Epidemiology

Key Findings from Wilson's Disease Epidemiological Analysis and Forecast 

• As per the analysis, it was observed that the United States accounted for the highest diagnosed prevalent cases of Wilson’s disease accounting for approximately 2,700 cases among the 7MM in 2024 followed by Japan with nearly 2,260 cases. On the other hand, Spain had the lowest diagnosed prevalent cases of Wilson’s disease.
• In 2025, the estimated incidence of Wilson's disease is approximately 1 per 30,000 population in the United States and 1 per 30,000–50,000 population in Europe.
• In 2024, there were approximately 86% symptomatic and 14% asymptomatic cases of Wilson’s disease in the 7MM.
• Wilson’s disease most commonly presents with hepatic manifestations, which occur in approximately 40–60% of patients, followed by neurological manifestations in about 40–50% of cases. Psychiatric manifestations are less common as the initial presentation, accounting for roughly 10–25% of patients. 
• While hepatic involvement remains the predominant clinical presentation, considerable overlap exists between hepatic, neurological, and psychiatric symptoms, reflecting the heterogeneous nature of the disease and often contributing to delays in diagnosis and treatment initiation. 

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of Wilson's disease, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• Wilson's Disease Patient Population Forecast

Report Key Strengths

• Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
• 11-year Forecast 
• Patient Burden Trends (By Geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Wilson's disease? What will be the growth opportunities across the 7MM concerning the patient population with Wilson's disease?
• What is the historical and forecasted Wilson's disease patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.